Medlab Clinical Ltd
ASX:MDC

Watchlist Manager
Medlab Clinical Ltd Logo
Medlab Clinical Ltd
ASX:MDC
Watchlist
Price: 6.6 AUD -4.21% Market Closed
Market Cap: 15.1m AUD

Medlab Clinical Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Medlab Clinical Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Medlab Clinical Ltd
ASX:MDC
EPS (Diluted)
AU$0
CAGR 3-Years
35%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
EPS (Diluted)
$0
CAGR 3-Years
17%
CAGR 5-Years
-27%
CAGR 10-Years
-10%
Mesoblast Ltd
ASX:MSB
EPS (Diluted)
$0
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
12%
CSL Ltd
ASX:CSL
EPS (Diluted)
$6
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
8%
Telix Pharmaceuticals Ltd
ASX:TLX
EPS (Diluted)
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
EPS (Diluted)
AU$0
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medlab Clinical Ltd
Glance View

Market Cap
15.1m AUD
Industry
Biotechnology

Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.

MDC Intrinsic Value
0.12 AUD
Overvaluation 98%
Intrinsic Value
Price

See Also

What is Medlab Clinical Ltd's EPS (Diluted)?
EPS (Diluted)
-0.9 AUD

Based on the financial report for Jun 30, 2024, Medlab Clinical Ltd's EPS (Diluted) amounts to -0.9 AUD.

What is Medlab Clinical Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
31%

Over the last year, the EPS (Diluted) growth was 69%. The average annual EPS (Diluted) growth rates for Medlab Clinical Ltd have been 35% over the past three years , 31% over the past five years .

Back to Top